Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Trametinib dimethyl sulfoxide + uprosertib by Novartis for Endometrial Cancer: Likelihood of Approval
Trametinib dimethyl sulfoxide + uprosertib is under clinical development by Novartis and currently in Phase I for Endometrial Cancer. According...